Q-omics provides the consensus-scored TMEM215 profile across patient tissues and cancer cell-line models. TMEM215 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TMEM215 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, TMEM215 RNA expression shows 13,790 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, THCA, and UVM as cancer lineages where TMEM215 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM215 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM215 survival associations across molecular data types. TMEM215 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM215 RNA expression–survival associations across cancer types. High TMEM215 expression shows unfavorable associations in MESO and BLCA, but favorable associations in BRCA, CESC, THCA and LUAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TMEM215 RNA expression.
This table summarizes TMEM215 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM215. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM215 shows higher tumor expression in THCA, BRCA, LUAD, COAD, BLCA and READ. The THCA box plot shows higher TMEM215 RNA expression in tumor versus normal tissue (log2 FC = +2.954, t-test p < 0.001).
This table shows molecular features associated with TMEM215 in patient tissues and cancer cell lines. In patient samples, TMEM215 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM215 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
